1318988-79-2

Upstream product

• 156775-41-6 chlorek kwasu 6-chloro-3-metylotio-1,1-diokso-1,4,2-benzoditiazyno-7-karboksylowego 
• 1318988-76-9 4-chloro-N'-(6-chloro-3-methylthio-1,1-dioxo-1,4,2-benzodithiazine-7-carbonyl)benzhydrazide 

Downstream Products

• 1318988-87-2 3-amino-6-chloro-7-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-1,1-dioxo-1,4,2-benzodithiazine 
• 1318988-99-6 3-amino-2-{2-benzylthio-4-chloro-5-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]benzenesulfonyl}guanidine 
• 1318989-21-7 N'-{2-benzylthio-4-chloro-5-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]benzenesulfonyl}-3,5-dimethyl-1H-pyrazole-1-amidine 
• 1318989-23-9 N'-{2-benzylthio-4-chloro-5-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]benzenesulfonyl}-3,4,5-trimethyl-1H-pyrazole-1-amidine 
• 1318989-24-0 N'-{2-benzylthio-4-chloro-5-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]benzenesulfonyl}-4-(2-ethoxycarbonylethyl)-3,5-dimethyl-1H-pyrazole-1-amidine 
• 1398564-76-5 1-{2-benzylthio-4-chloro-5-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]benzenesulfonyl}-3-hydroxyguanidine 

Relevant academic research and scientific papers

Novel 3-amino-6-chloro-7-(azol-2 or 5-yl)-1,1-dioxo-1,4,2-benzodithiazine derivatives with anticancer activity: Synthesis and QSAR study

A series of new 3-amino-6-chloro-7-(azol-2 or 5-yl)-1,1-dioxo-1,4,2-benzodithiazine derivatives 5a-j have been synthesized and evaluated in vitro for their antiproliferative activity at the U.S. National Cancer Institute. The most active compound 5h showe

Synthesis and antitumor activity of novel N'-(2-benzylthiobenzenesulfonyl)- lH-pyrazole-l-amidine derivatives

A series of N'-(2-benzylthio-4-chlorobenzenesulfonyl)-lH-pyrazole-l- amidines (23-36) were synthesized by the reaction of 3-amino-2-(benzenesulfonyl) guanidines (18-22) with adequate l, 3-diketones. The compounds 23, 24, 26, 30, 31, 34 and 35 were tested in vitro in the full NCI 60 cell panel. The most potent compound in the series (26) showed substantial activity toward some cell lines of leukemia and cancer cells of lung, colon, CNS, melanoma, renal, prostate and breast (GI50 in the range 2.30-9.47 μM). The Japan Institute of Heterocyclic Chemistry.